摘要
目的比较氯雷他定片联合布地奈德鼻喷雾剂和曲安奈德鼻喷雾剂治疗成人中-重度变应性鼻炎(AR)的临床疗效。方法将156例年龄为18-30岁的中-重度持续性AR患者随机分为布地奈德(BUD)组和曲安奈德(TRI)组,每组各78例。在口服氯雷他定片10 mg/d的基础上,BUD组患者使用布地奈德鼻喷剂256μg/d,TRI组患者使用曲安奈德鼻喷剂220μg/d。应用鼻炎症状评分体系对两组患者进行评价,评分越低症状越轻。结果治疗4周后,BUD组患者的症状评分略低于TRI组,但差异无显著性(P〉0.05)。结论氯雷他定片联合布地奈德鼻喷雾剂和曲安奈德鼻喷雾剂治疗成人中-重度AR均有较好的临床疗效,但曲安奈德鼻喷雾剂可能更具药物经济学优势。
Objective To compare the clinical efficacy in adult moderate to severe allergic rhinitis (AR) by loratadine tablets combined budesonide nasal spray or triamcinolone acetonide nasal spray. Method 156 patients who were 18 to 30 years old were randomly divided into BUD group and TRI group, 78 patients each group. In oral loratadine tablets 10 mg/d, based on, BUD group used budesonide nasal spray 256 μg/d, TRI group used triamcinolone acetonide nasal spray 220 μg/d. Application rhinitis symptom score evaluation system, the lower score the lighter symptoms. Result After 4 weeks of treatment, the symptoms of BUD group score was slightly lower than TRI group numerically, but the result was not statistically significant (P 〉 0.05). Conclusion Loratadine with budesonide nasal spray or triarncinolone acetonide nasal spray have satisfactory therapeutic effect in adults moderate to severe allergic rhinitis, but triamcinolone acetonide nasal spray may has more pharmacoeconomics advantage.
出处
《中国医学前沿杂志(电子版)》
2014年第8期142-144,共3页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)